Elevated Rate Pacing of Cardiac Amyloidosis

Part of paid clinical trials in Minneapolis, Minnesota.

Sponsor
University of Minnesota
Study ID
NCT07583823
Status
Recruiting
Apply to this trial

Conditions

  • Cardiac Amyloidosis
  • Pacemaker

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pacemaker Rate — OTHER
    CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

Study Details

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Key Dates

Start date
Oct 10, 2025
Status verified
May 2026
Primary completion
Oct 10, 2026
Completion
Oct 10, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Elevated Pacemaker Rate
    CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.

Primary Outcome Measure

Kansas City Cardiomyopathy Questionnaire Score [ Time Frame: Month 4 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MinnesotaMinneapolisMinnesota55455
Meghan Muscala
[email protected]
612-626-5863

Find similar trials in Minneapolis, MN

By research site
University of Minnesota· Minneapolis, MN

Related Studies